Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows
Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2.
Benzinga ·